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ORIGINAL INVESTIGATION
Cardiovascular disease in a nationwide 
population of Danish women with polycystic 
ovary syndrome
Dorte Glintborg1,2* , Katrine Hass Rubin3, Mads Nybo4, Bo Abrahamsen3,5 and Marianne Andersen1,2
Abstract 
Background: Polycystic ovary syndrome (PCOS) is associated with obesity and low grade inflammation and the risk 
for cardiovascular disease (CVD) could be increased in PCOS.
Methods: National register-based study including women with PCOS and no previous diagnosis of CVD, hyperten-
sion, or dyslipidemia. PCOS Denmark (N = 18,112) included women with PCOS in the Danish National Patient Register. 
PCOS Odense University Hospital (OUH, N = 1165) was an embedded cohort including premenopausal women with 
PCOS and clinical and biochemical examination. Three age-matched controls were included per patient in PCOS 
Denmark (N = 52,769). The main study outcome was CVD events including hypertension and dyslipidemia defined 
according to nationwide in- and outpatient hospital contact diagnosis codes and/or inferred from filled medicine 
prescriptions.
Results: The age at inclusion was median (quartiles) 29 (23–35) years and follow up was 11.1 (6.9–16.0) years. The 
Hazard ratio (95% CI) for development of CVD in PCOS Denmark was 1.7 (1.7; 1.8) (P < 0.001) and the total event rate 
of CVD was 22.6 per 1000 patient years in PCOS Denmark vs. 13.2 per 1000 patient years in controls (P < 0.001). The 
median age at diagnosis of CVD was 35 (28–42) years in PCOS Denmark vs. 36 (30–43) years in controls (P < 0.001). 
Obesity, diabetes, and infertility, and previous use of oral contraceptives were associated with increased risk of devel-
opment of CVD in PCOS Denmark (P < 0.001). Women in PCOS OUH resembled women in PCOS Denmark regarding 
risk of CVD. Age, BMI, blood pressure, lipid status, and glycemic status predicted development of CVD in PCOS OUH.
Conclusion: The event rate of CVD including hypertension and dyslipidemia was higher in PCOS compared to con-
trols. The risk of developing CVD must be considered even in young women with PCOS.
Keywords: Polycystic ovary syndrome, Register-based, ICD-10, HT, Cardiovascular disease, Medicine prescriptions, 
Nationwide
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Introduction
The definition of polycystic ovary syndrome (PCOS) 
includes irregular ovulation, hyperandrogenism, and/
or polycystic ovaries when other etiologies are excluded 
[1]. The pathogenesis of PCOS includes insulin resist-
ance and low grade inflammation [2], and women with 
PCOS have increased risk of metabolic syndrome [3, 4]. 
Insulin resistance and low grade inflammation in PCOS 
could be associated with increased risk of development 
of cardiovascular disease (CVD). The odds ratio (OR) 
for CVD in PCOS varied from 1.3 to 2.0 in recent meta-
analyses [5–8], but two of the studies reported no statisti-
cally significant association between PCOS and CVD [5, 
6]. The absolute risk of CVD in premenopausal women is 
low and previous studies may have had too little power to 
detect increased risk of CVD in PCOS [6]. Furthermore, 
several risk factors modify the metabolic risk in PCOS. 
Obesity is closely related to insulin resistance and inflam-
mation [9]. Lean women with PCOS did not have an 
increased risk of developing type 2 diabetes compared to 
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age-matched controls [4, 10], and the risk for developing 
CVD in lean women with PCOS needs to be determined. 
It is recommended that all women with PCOS should be 
screened for metabolic syndrome upon diagnosis [11], 
but measurement of lipids in young women with PCOS 
rarely changed clinical care [12]. Also the importance of 
individual risk markers such as high blood pressure (BP), 
dyslipidemia, and elevated blood glucose for future devel-
opment of CVD in PCOS remains to be established. The 
risk of CVD could also be modified by medical treatment 
of PCOS. Fasting insulin levels were unchanged during 
treatment with oral contraceptives (OCP) in PCOS [13], 
but treatment with OCP has been reported to be asso-
ciated with weight gain [14], increased thrombin genera-
tion [15] and increased risk of venous thromboembolism 
[16, 17], and use of OCP could therefore have an adverse 
effect on CVD risk.
The aim of the present register-based study was to 
investigate the risk of developing CVD in women with 
PCOS and possible modifying effects of obesity, comor-
bidity, and prescription of OCP. Possible associations 
between baseline metabolic risk profile and later devel-
opment of CVD were investigated in a well-described 
representative subgroup of patients with hyperandrogen-
ism and/or PCOS.
Materials and methods
The study design and baseline data for this study have 
recently been reported in detail [18] and data regarding 
development of type 2 diabetes and incident fractures 
[10, 19] in the study cohort has recently been published. 
We used an observational register-based cohort drawn 
from Danish national health registers including two 
patient populations with PCOS and one control popula-
tion (Fig. 1). PCOS Denmark included all women in Den-
mark aged 12–60  years, who were diagnosed through a 
hospital contact with PCOS (E282) and/or hirsutism 
(L680) between January 1st 1995 and the end of 2012. 
PCOS Odense University Hospital (OUH) included an 
embedded local sub-cohort of women with PCOS and/
or hirsutism treated at OUH with available clinical and 
biochemical information. For each patient in PCOS Den-
mark (and in PCOS OUH), three control women born in 
the same year as the patient were randomly drawn from 
the civil population register. Controls were assigned the 
index date (date of first PCOS diagnosis) of their matched 
PCOS cases and should be alive at the index date of their 
PCOS case.
Assays in PCOS OUH
These have been described recently [10, 18] and are pre-
sented in the Additional file 1. During 1997–2003, an oral 
glucose tolerance test (OGTT) was part of the routine 
evaluation program for newly referred women with 
PCOS [20].
The Danish health registries
All Danish individuals are assigned a unique personal 
identification number and data from national regis-
ters can therefore be linked at an individual level. We 
retrieved information about hospital contacts and filled 
medicine prescriptions along with dates of death if appli-
cable, for women with PCOS and control subjects from 
National Patient Register (NPR), the National Prescrip-
tion Registry and the National Cause of Death Register 
from 1995 to December 31st 2015.
Outcome
The primary outcome was CVD defined as at least one 
of the following criteria: (1) the presence of a CVD diag-
nosis in NPR according to ICD10: E78 (dyslipidemia), 
G45–G46 (TCI), I10–13 (essential hypertension and 
hypertension with complications), I20 (angina), I21–25 
(myocardial infarction and ichemic coronary disease), 
I26 (lung embolism), I50 (incompensatio cordis), I63–I64 
(cerebral infarction), I65–I66 (occlusion of vertebral and 
cerebral arteries), I80–82 (venous thrombosis) or (2) pre-
scription of drugs for treatment of CVD according to the 
National Prescriptions Registry database: antithrombot-
ics (B01), antihypertensives (C02: alpha-blockers, C07: 
beta-blockers, C08: calcium-antagonists, C09: renin-
angiotensin blockers), C10: antilipids. Patients should be 
medically treated for a certain time period and therefore, 
two or more medicine withdrawals should occur within 
the same ATC group to be included.
Secondary outcome
The risk of CVD excluding hypertension and dyslipi-
demia. This outcome was defined as at least one of the 
following criteria: (1) the presence of a CVD diagnosis in 
NPR according to ICD10: G45–G46 (TCI), I20 (angina), 
I21–25 (myocardial infarction and ichemic coronary dis-
ease), I26 (lung embolism), I50 (incompensatio cordis), 
I63–I64 (cerebral infarction), I65–I66 (occlusion of ver-
tebral and cerebral arteries), I80–82 (venous thrombo-
sis), or (2) prescription of drugs for treatment of CVD 
according to the National Prescriptions Registry data-
base: antithrombotics (B01). Patients should be medi-
cally treated for a certain time period and therefore, two 
or more medicine withdrawals should occur within the 
same ATC group to be included.
Exclusion criteria
Participants with CVD events occurring before and 
up till 3  months after the index date were excluded. 
Furthermore, women with the diagnoses E221 
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(hyperprolactinemia), E220 (acromegaly), E24 (Cush-
ing’s syndrome), E25 (adrenogenital syndrome), and Q96 
(Turner syndrome) were excluded from all study cohorts.
Exposure
A baseline diagnosis of obesity (E66), type 1 and type 2 
diabetes and gestational diabetes (E10, E13, E11, E14, 
O24), infertility (N97, Z350), presence of comorbidity 
(defined as Charlson index ≥ 1), and use of OCP were 
used as exposures. Use of OCP [ATC codes G03AA and 
G03AB (combined progesterone and estrogen OCP), and 
G03HB01 (OCP containing cyproterone)] was defined 
as ≥ 2 dispenses of prescriptions in the National Prescrip-
tion Registry (a minimum of 6  months treatment with 
OCP). The Charlson Comorbidity Index is based on 19 
comorbid conditions [21] and was calculated from the 
ICD-10 operationalization by Quan et al. [22]. All covari-
ates were defined before the index date.
Statistical analyses
Descriptive analyses for categorical variables were pre-
sented as frequencies and difference between PCOS and 
controls was evaluated by Chi square test. Continuous 
variables were tabulated as medians (with quartiles, Q1 
and Q3) and nonparametric test on the equality of medi-
ans were used to test for differences between groups. P 
values below 0.05 were considered statistically significant.
Cox proportional hazard models were used to calcu-
late incidence rates, hazard ratios (HR) and 95% confi-
dence intervals (95% CIs) and corresponding P values 
for outcomes. The regression analyses including PCOS 
Denmark and controls with CVD as the outcome were 
carried out crude and adjusted for one of the exposures 
obesity, diabetes, infertility, comorbidity and use of OCP, 
and finally adjusted for all four variables: Obesity, diabe-
tes, infertility and use of OCP. The diagnosis codes for 
diabetes and CVD are included as part of the Charlson 
Fig. 1 Flowchart of included women with PCOS and controls. CVD was defined as at least one of the following criteria: (1) the presence of a CVD 
diagnosis in NPR according to ICD10: E78 (dyslipidemia), G45–G46 (TCI, stroke), I10–13 (essential hypertension and hypertension with complica-
tions), I20 (angina), I21–25 (myocardial infarction and ichemic coronary disease), I26 (lung embolism), I50 (incompensatio cordis), I63–I64 (cerebral 
infarction), I65–I66 (occlusion of vertebral and cerebral arteries), I80–82 (venous thrombosis) or (2) prescription of drugs for treatment of CVD 
according to the National Prescriptions Registry database: antithrombotics (B01), antihypertensives (C02: alpha-blockers, C07: beta-blockers, C08: 
calcium-antagonists, C09: renin-angiotensin blockers), C10: antilipids. Two or more medicine withdrawals should occur within the same ATC group 
to be included
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index and therefore we did not adjust for Charlson score 
in the regression models. Regression analyses were 
repeated with CVD excluding hypertension and dyslipi-
demia as outcomes. The matching of PCOS and controls 
was taken into account by estimating stratified baseline 
hazard for each matching set.
The Cox proportional hazard analyses (regression 
analyses) in the PCOS OUH cohort were carried out 
crude and adjusted for age and BMI. Analyses were con-
ducted using STATA 14 (StataCorp 2015). Data were 
anonymized according to Danish law and regulations, 
and therefore analyses were performed through a remote 
VPN access to Statistics Denmark.
Ethics
The core study was an open register-based cohort study. 
The study did not need approval from the local Ethics 
committee or Institutional Review Board by Danish law. 
The study was approved by the Data Protection Agency 
and by Statistics Denmark, Project No. 704175.
Results
The flow chart of included women is shown in Fig. 1. A 
total of 18,112 women with PCOS (PCOS Denmark and 
the embedded cohort PCOS OUH, N = 1165) and 52,769 
controls were included in the study.
PCOS vs. controls (Additional file 1: Appendix Table S1)
The median age of women in PCOS Denmark was 
29 years. By definition, the age was comparable in PCOS 
Denmark vs. controls. Women in PCOS Denmark had 
higher prevalence of ICD10 codes and medicine prescrip-
tions related to the metabolic syndrome occurring before 
the index date compared to controls. The prevalence of 
comorbidity and infertility was higher in PCOS and the 
prescription of OCP and drugs for fertility treatment and 
the number of births before the index date (23% vs. 19% 
had ≥ 1 births) was higher in PCOS than controls.
Women in PCOS Denmark resembled women in PCOS 
OUH regarding age and ICD10 codes for the metabolic 
syndrome and comorbidity before the index date, but 
they had higher average number of births, lower preva-
lence of infertility diagnoses and lower prevalence of 
antidiabetic prescriptions.
Baseline clinical and biochemical data in PCOS OUH 
(Additional file 1: Appendix Table S2)
The median age of women in PCOS OUH was 29 years, 
BMI was 27.0  kg/m2, 52% had waist ≥ 88  cm, 61% had 
BMI ≥ 25  kg/m2, 38% had elevated systolic BP, 34% had 
elevated diastolic BP, and 18% had TG ≥ 1.7 mmol/L.
CVD event rates (Table 1)
The median (Q1–Q3) follow up duration was 11.1 (6.9–
16.0) years. The incidence rate of CVD was 22.6/1000 
person years (PY) in PCOS OUH, 22.0/1000 PY in PCOS 
Denmark, and 13.2/1000 PY in controls (P < 0.001 PCOS 
Denmark vs. controls). The incidence rate for CVD 
excluding hypertension and dyslipidemia was 6.4/1000 
PY in PCOS Denmark vs. 4.5/1000 PY in controls 
(P < 0.001).
Baseline characteristics according to subsequent 
development of CVD in PCOS OUH (Table 2)
Women in PCOS OUH who developed CVD were sig-
nificantly older, more obese (higher BMI and waist cir-
cumference), had higher BP (systolic and diastolic), a 
more adverse lipid profile (LDL, cholesterol, and triglyc-
erides), higher glucose and insulin levels (HbA1c, fasting 
insulin and glucose, and HOMA-ir), and lower prolactin 
levels at baseline compared to women in PCOS OUH 
and no development of CVD, whereas testosterone levels 
(free and total) and SHBG were comparable in the two 
groups. Development of CVD was dependent of base-
line metabolic risk profile (BMI, waist, systolic and dias-
tolic BP, and triglycerides), but development of CVD was 
also observed in women with PCOS and BMI < 25  kg/
m2, waist < 88  cm, systolic BP < 130  mmHg, diastolic 
BP < 85 mmHg and triglycerides < 1.7 mmol/L.
Baseline characteristics according to development 
of CVD in PCOS Denmark and controls (Table 3): women 
with development of CVD including hypertension 
and dyslipidemia in PCOS Denmark vs. controls
The median age at diagnosis of CVD was significantly 
lower in PCOS Denmark vs. controls (35 vs. 36  years, 
P < 0.001) and 90% vs. 88% were aged < 50 years at CVD 
diagnosis, respectively (P < 0.001). The diagnoses obesity, 
diabetes, infertility, presence of comorbidity, and pre-
scription of OCP were significantly more prevalent in 
women with PCOS and development of CVD compared 
to controls with development of CVD. When hyperten-
sion and dyslipidemia was excluded from the diagnosis of 
CVD, the median age of diagnosis was 36 vs. 38 years in 
PCOS vs. controls (P < 0.001).
PCOS Denmark and development of CVD yes vs. no
Women in PCOS Denmark who developed CVD were 
significantly older than women in PCOS Denmark with-
out development of CVD (35 vs. 28 years, P < 0.001), the 
diagnoses obesity, diabetes, and presence of comorbid-
ity were more common, whereas a diagnosis of infertil-
ity and use of OCP was lower. When hypertension and 
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dyslipidemia was excluded from the diagnosis of CVD, 
the diagnosis obesity had similar prevalence at baseline 
irrespective of later CVD diagnosis (P = 0.15).
Proportional hazard regression analyses
The HR for development of CVD was 1.7 (1.6; 1.8) in 
PCOS Denmark vs. controls (Table 4). The HR for CVD 
excluding hypertension and dyslipidemia was 1.4 (1.3; 
1.5). In regression models, a diagnosis of obesity, diabe-
tes, infertility, and a Charlson index ≥ 1 at baseline was 
associated with a higher risk of CVD. Similar findings 
were found for CVD excluding hypertension and dys-
lipidemia. Prescription of OCP at baseline was associated 
with increased risk of CVD, but did not predict CVD 
excluding hypertension and dyslipidemia.
In PCOS OUH, age, obesity (BMI, waist), BP (systolic 
and diastolic), lipid status (LDL, cholesterol, TG), prolac-
tin, blood glucose (fasting, 2 h), insulin (fasting, HOMA-
ir) were significant predictors for development of CVD 
(Table 5). When models were corrected for age and BMI; 
diastolic BP, lipid status (LDL, cholesterol, TG), and 2 h 
BG were the best predictors of development of CVD. 
Similar significant results were found for CVD excluding 
hypertension and dyslipidemia.
Discussion
In the present study, we demonstrate a higher incidence 
rate of CVD including dyslipidemia and hypertension in 
Danish women with PCOS compared to age-matched 
controls. The OR for development of CVD including 
hypertension and dyslipidemia was 1.7 in PCOS, and a 
baseline diagnosis of obesity, diabetes, infertility, Charl-
son index ≥ 1, and use of OCP were significant, inde-
pendent predictors of CVD. In a representative subgroup 
of women with PCOS from our outpatient clinic, the risk 
of CVD was adversely affected by higher BMI, waist, BP, 
lipids, insulin, and glucose levels upon PCOS diagno-
sis, whereas baseline testosterone levels did not predict 
risk of CVD. The PCOS OUH cohort was relatively lean 
(median BMI 26.9 kg/m2) upon PCOS diagnosis and the 
average age was 29  years, but 22% women developed 
CVD during a median follow up of 11.1 years. When the 
diagnoses hypertension and dyslipidemia were excluded 
from the study outcome, the OR for development of CVD 
was 1.4 in PCOS and 7% women with PCOS developed 
CVD during follow up compared to 5% controls.
To our knowledge this is the first nationwide study 
to describe risk of developing CVD in a predominantly 
premenopausal study population of PCOS. We could 
Table 1 Event rates of CVD in PCOS OUH, PCOS Denmark and controls
IR: incidence rate. Presented per 1000 PY (person years)
VTE: venous thromboembolism
HT: hypertension defined as ICD10 codes I10–13 OR prescription of C02, C07–09 (two or more medicine withdrawals within the same ATC group 3 months or later 
after the index date)
DL: dyslipidemia defined as (ICD 10 code) E78 OR prescription of C10 (two or more medicine withdrawals within the same ATC group 3 months or later after the index 
date)
Pa: Chi square test between PCOS Denmark and controls
Pb: Chi square test between PCOS OUH and controls
PCOS OUH
(N = 1159)
PCOS Denmark
(N = 17,995)
Controls
(N = 52,329)
Pa Pb
N (%) IR N (%) IR N (%) IR
CVD events 264 (23) 22.6 3970 (22) 22.0 7344 (14) 13.2 < 0.001 0.54
CVD (HT and DL excluded) 71 (6) 5.4 1290 (7) 6.4 2678 (5) 4.5 < 0.001 0.16
ICD10 CVD, total 121 (10) 9.5 1727 (10) 8.7 3089 (6) 5.2 < 0.001 0.31
E 78 (dyslipidemia) 33 (3) 2.5 431 (2) 2.1 653 (1) 1.1 < 0.001 0.30
G45–46, I63–66 (TCI, stroke) 16 (1) 1.2 206 (1) 1.0 524 (1) 0.9 0.102 0.44
I10–13 (hypertension) 77 (7) 5.9 1004 (6) 4.9 1484 (3) 2.5 < 0.001 0.10
I20–25 (CVD) 20 (2) 1.5 364 (2) 1.8 854 (2) 1.4 0.001 0.46
I26 (VTE lung) 4 (0.4) 0.3 97 (0.5) 0.5 151 (0.3) 0.2 < 0.001 0.35
I50 (incompensatio) 0 Na 47 (0.3) 0.2 200 (0.4) 0.3 0.018 0.07
I80–82 (VTE extremities) 17 (1) 1.3 216 (1) 1.0 451 (1) 0.7 < 0.001 0.39
Medical treatment 247 (21) 20.8 3643 (20) 20.0 6656 (13) 11.9 < 0.001 0.35
Antithrombotics (B01) 50 (4) 3.8 940 (5) 4.6 1887 (4) 3.2 < 0.001 0.15
Antihypertensive (C02, C07–09) 189 (16) 15.4 2744 (15) 14.5 5087 (10) 8.9 < 0.001 0.30
Antilipids (C10) 121 (10) 9.4 1601 (9) 8.1 2833 (5) 4.8 < 0.001 0.06
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confirm results from recent studies where the OR for 
CVD was increased in women with PCOS [5–8, 23, 24]. 
However, the present study design also allowed us to test 
the modifying effect of several risk factors for the devel-
opment of CVD in PCOS.
BMI and metabolic risk in PCOS
We found that the cardiovascular risk in PCOS was 
closely associated with BMI. In PCOS Denmark, a base-
line ICD10 diagnosis of obesity resulted in a HR between 
2.4 and 2.7 for CVD. Further, we noted that 24% of 
women in PCOS OUH that developed CVD were lean 
by the time of PCOS diagnosis. These results were in 
accordance with previous studies who reported that the 
risk of CVD and/or stroke was attenuated but not nor-
malized in women with PCOS after adjusting for BMI [5, 
7, 24]. Our results regarding BMI and CVD were some-
what different from data regarding the risk of T2D in 
lean women with PCOS, where the risk of T2D was < 1% 
at time of PCOS diagnosis [20, 25] and the risk of T2D 
development during follow up was not increased com-
pared to age-matched controls [4, 10]. Therefore, our 
Table 2 Baseline clinical and biochemical characteristics according to subsequent development of CVD in PCOS OUH
Data presented as median (Q1–Q3)
BP blood pressure, LDL low density lipoprotein, HDL high density lipoprotein, 2 h 2 hours (during oral glucose tolerance test), HOMA-ir homeostasis model assessment 
of insulin resistance, SHBG Sex hormone-binding globulin
P#: non-parametric test on the equality of medians
P¤: Chi squared test
Development of CVD P#
Yes
N = 264
No
N = 895
Baseline characteristics N (%) Median (Q1–Q3) N (%) Median (Q1–Q3)
Age (years) 230 (100) 35 (28–39) 935 (100) 27 (21–33) < 0.001
BMI (kg/m2) 245 (93) 30.2 (25.1–35,2) 831 (93) 26.1 (22.6–31.1) < 0.001
Waist (cm) 134 (51) 100 (84–110) 587 (66) 87 (77–100) < 0.001
Systolic BP (mmHg) 148 (56) 130 (120–140) 624 (70) 123 (114–131) 0.002
Diastolic BP (mmHg) 148 (56) 85 (78–92) 650 (70) 80 (70–86) < 0.001
LDL cholesterol (mmol/L) 184 (70) 3.2 (2.6–3.9) 663 (74) 2.6 (2.1–3.1) 0.275
HDL cholesterol (mmol/L) 186 (70) 1.3 (1.1–1.6) 663 (74) 1.4 (1.1–1.6) < 0.001
Cholesterol (mmol/L) 186 (70) 5.2 (4.5–5.9) 674 (75) 4.5 (4.0–5.1) < 0.001
Triglycerides (mmol/L) 186 (70) 1.3 (0.9–1.9) 662 (74) 1.0 (0.7–1.3) 0.026
Prolactin (µg/L) 223 (85) 6 (5–9) 731 (82) 7 (5–10) 0.010
HbA1c (mmol/mol) 108 (41) 37 (33–42) 463 (52) 33 (31–37) 0.298
Fasting blood glucose (mmol/L) 150 (57) 4.7 (4.2–5.0) 384 (43) 4.6 (4.3–5.0) 0.012
2 h blood glucose (mmol/L) 149 (56) 6.4 (5.3–7.6) 373 (42) 6.0 (5.2–6.9) 0.001
Fasting insulin (pmol/L) 157 (60) 60 (40–114) 410 (46) 53 (36–82) 0.002
HOMA-ir (pmol mmol/L2) 152 (58) 14.8 (9.1–25.9) 388 (43) 11.3 (7.6–17.1) 0.330
Total testosterone (nmol/L) 170 (64) 1.7 (1.2–2.3) 655 (73) 1.8 (1.3–2.5) 0.708
SHBG (nmol/L) 244 (92) 45 (30–64) 829 (93) 44 (31–67) 0.367
Free testosterone (nmol/L) 167 (63) 0.032 (0.021–0.049) 644 (72) 0.033 (0.021–0.050) 0.012
P¤
BMI ≥ 25 kg/m2 186 (76) 469 (56) < 0.001
BMI < 25 kg/m2 59 (24) 362 (44)
Waist ≥ 88 cm 94 (71) 277 (47) < 0.001
Waist < 88 cm 40 (30) 310 (53)
Systolic BP ≥ 130 mmHg 84 (57) 205 (33) < 0.001
Systolic BP < 130 mmHg 64 (43) 420 (67)
Diastolic BP ≥ 85 mmHg 77 (52) 186 (30) < 0.001
Diastolic BP < 85 mmHg 71 (48) 438 (70)
Triglycerides ≥ 1.7 mmol/L 63 (34) 93 (15) < 0.001
Triglycerides < 1.7 mmol/L 123 (66) 569 (86)
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data suggest that prospective screening for CVD is indi-
cated also in lean women with PCOS, whereas prospec-
tive OGTT, fasting glucose or HbA1c measurements may 
not be necessary.
Blood pressure
Screening for metabolic syndrome includes measurement 
of BP, lipid status and assessment of glucose metabolism. 
In regression analyses, high baseline BP was an important 
predictor of CVD development. Furthermore, more than 
30% women in PCOS OUH had BP ≥ 130/85 mmHg, and 
we previously reported a three times increased risk of the 
ICD10 code hypertension in PCOS Denmark vs. controls 
at baseline [18]. In a Chinese population of women with 
PCOS, women with hypertension had higher lipid, glu-
cose, insulin, and HOMA-ir levels than women without 
hypertension also after adjusting for BMI [26], which 
suggested that elevated BP was a marker of metabolic 
risk. Our results support that BP should be measured in 
all women with PCOS irrespective of BMI.
Lipids
Elevated TG levels ≥ 1.7  mmol/L were found in 18% 
women in PCOS OUH, and in multiple regression anal-
yses TG, LDL and total cholesterol levels were the best 
predictors of development of CVD and remained signif-
icant after adjusting for age and BMI. However, 66% of 
women in PCOS OUH that developed CVD had baseline 
TG < 1.7 mmol/L, which supported that other risk mark-
ers than lipid profile determined CVD risk in PCOS. 
Previous studies estimated that 70% women with PCOS 
had borderline or high lipid levels [27], but dyslipidemia 
Table 3 Characteristics according to development of CVD in PCOS Denmark and controls
Comorbidity was defined as a Charlson index ≥ 1
ICD 10 codes OCP (oral contraceptives): G03AA, G03AB, G03HB01
Hypertension (HT) defined as ICD10 codes I10–13 OR prescription of C02, C07–09
Dyslipidemia (DL) defined as (ICD 10 code) E78 OR prescription of C10
Two or more medicine withdrawals should occur within the same ATC group 3 months or later after the index date)
Diabetes defined as type 1 or type 2 diabetes or gestational diabetes according to ICD10: E10, E11, E13, E14, O24
P values obtained with Chi squared test for categorical variables and non-parametric test on the equality of medians for continuous variables
Development of CVD in PCOS Development of CVD in controls PCOS vs. 
controls
P
A vs. B
P
A vs. C
Total Yes
A
No
B
Total Yes
C
No
D
Development of CVD 17,995 3970 14,025 52,329 7344 44,985
Age at diagnosis (years)
Median (Q1, Q3)
29 (23–35) 35 (28–42) 28 (22–33) 29 (23–35) 36 (30–43) 28 (23–33) 0.009 < 0.001 < 0.001
N (%) N (%) N (%) N (%) N (%) N (%)
Age < 50 years 17,331 (96) 3591 (90) 13,740 (98) 50,718 (97) 6496 (88) 44,222 (98) < 0.001 < 0.001 0.001
Baseline characteristics
 Obesity 2005 (11) 444 (11) 1561 (11) 648 (1) 121 (2) 527 (1) < 0.001 0.924 < 0.001
 Diabetes 448 (3) 198 (5) 250 (2) 367 (1) 163 (2) 204 (1) < 0.001 < 0.001 < 0.001
 Infertility 4158 (23) 751 (19) 3407 (24) 2007 (4) 259 (4) 1748 (4) < 0.001 < 0.001 < 0.001
 Comorbidity 796 (4) 215 (5) 581 (4) 1646 (3) 253 (3) 1393 (3) < 0.001 0.001 < 0.001
 Oral contraceptives 10,432 (58) 1752 (44) 8680 (62) 16,005 (31) 1652 (23) 14,353 (32) < 0.001 < 0.001 < 0.001
Development of CVD (HT and DL 
excluded)
17,995 1290 16,705 52,329 2678 49,651
Age at diagnosis (years)
Median (Q1, Q3)
29 (23–35) 36 (29–44) 29 (23–35) 29 (23–35) 38 (31–46) 28 (23–34) 0.009 < 0.001 < 0.001
N (%) N (%) N (%) N (%) N (%) N (%)
Age < 50 years 17,331 (96) 1098 (85) 16,233 (97) 50,718 (97) 2235 (83) 48,4834 (98) < 0.001 < 0.001 0.182
Baseline characteristics
 Obesity 2005 (11) 128 (10) 1877 (11) 648 (1) 39 (1) 609 (1) < 0.001 0.149 < 0.001
 Diabetes 448 (3) 60 (5) 388 (2) 367 (1) 57 (2) 310 (1) < 0.001 < 0.001 < 0.001
 Infertility 4158 (23) 217 (17) 3941 (24) 2007 (4) 95 (4) 1912 (4) < 0.001 < 0.001 < 0.001
 Comorbidity 796 (4) 98 (8) 698 (4) 1646 (3) 105 (4) 1541 (3) < 0.001 < 0.001 < 0.001
 Oral contraceptives 10,432 (58) 497 (39) 9935 (60) 16,005 (31) 513 (19) 15,492 (31) < 0.001 < 0.001 < 0.001
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depends on for example ethnicity [28] and age [29]. The 
inclusion of a relatively lean and young study population 
of predominantly Nordic origin could have affected our 
study results. Our data support the importance of per-
forming a baseline lipid profile in PCOS as risk assess-
ment, but treatment with statins is rarely indicated in 
women < 35 years [12].
Insulin resistance and glycemic status
HbA1c, fasting insulin, and HOMA-ir were higher at 
baseline evaluation in women in PCOS OUH with devel-
opment of CVD compared to those not diagnosed with 
CVD. In multiple regression analyses, 2  h BG, fasting 
insulin, and HOMA-ir predicted development of CVD 
after adjusting for age and BMI, whereas HbA1c did not 
predict CVD risk. We could not confirm that HbA1c is a 
better predictor of CVD than fasting or 2 h glucose [30]. 
Median HbA1c was however relatively low in our study 
cohort, which could have affected study results. In PCOS 
Denmark, a baseline diagnosis of diabetes increased the 
risk of CVD more than threefold, confirming that women 
with PCOS and diabetes need special attention regarding 
risk of CVD.
Age
Age was a significant predictor for CVD in the present 
study, but the effect was moderate as the median age at 
CVD diagnosis was only 1 year lower in PCOS Denmark 
vs. controls and 90% vs. 88% was aged < 50 years at CVD 
diagnosis. BMI and age are closely associated [29, 31], but 
the significant association between age and CVD devel-
opment remained significant after adjusting for BMI. Our 
data could reflect that hypertension may be diagnosed at 
a relatively young age, especially as BP is measured in all 
women during pregnancy, but the exclusion of hyperten-
sion as a CVD outcome still resulted in a relatively low 
Table 4 Crude and adjusted Hazard ratios in PCOS Denmark (N = 18,112) and controls (N = 52,769) and development 
of CVD
Predictors for development of CVD in PCOS Denmark and controls
Comorbidity was defined as a Charlson index ≥ 1
Hazard ratios are presented for crude models and models corrected for obesity, diabetes, infertility, and use of OCP at the index date
Diabetes defined as type 1 or type 2 diabetes or gestational diabetes according to ICD10s (E10, E11, E13, E14, O24)
Crude HR (95% CI) Adjusted HR
HR (95% CI)
Adjusted HR
HR (95% CI)
Adjusted HR
HR (95% CI)
Adjusted HR
HR (95% CI)
Adjusted HR
HR (95% CI)
Adjusted HR
HR (95% CI)
Outcome: CVD
 PCOS (yes/no) 1.7 (1.7; 1.8)
P < 0.001
1.6 (1.5; 1.7)
P < 0.001
1.7 (1.6; 1.8)
P < 0.001
1.7 (1.6; 1.8)
P < 0.001
1.7 (1.6; 1.7)
P < 0.001
1.7 (1.6; 1.8)
P < 0.001
1.6 (1.5; 1.6)
P < 0.001
Predictors
 Obesity 2.7 (2.4; 3.1)
P < 0.001
2.4 (2.1; 2.7)
P < 0.001
 Diabetes (yes/no) 4.9 (4.1; 5.9)
P < 0.001
4.4 (3.6; 5.3)
P < 0.001
 Infertility (yes/no) 1.2 (1.1; 1.3)
P = 0.001
1.0 (0.9; 1.1)
P = 0.802
 Comorbidity 1.6 (1.4; 1.8)
P < 0.001
 OCP (yes/no) 1.1 (1.1; 1.2)
P < 0.001
1.1 (1.1; 1.2)
P < 0.001
Outcome: CVD (HT and DL excluded)
 PCOS (yes/no) 1.4 (1.3; 1.5)
P < 0.001
1.3 (1.2; 1.4)
P < 0.001
1.4 (1.3; 1.5)
P < 0.001
1.4 (1.3; 1.5)
P < 0.001
1.4 (1.3; 1.8)
P < 0.001
1.4 (1.3; 1.5)
P < 0.001
1.3 (1.2; 1.4)
P < 0.001
Predictors
 Obesity 2.4 (1.9; 3.1)
P < 0.001
2.1 (1.7; 2.7)
P < 0.001
 Diabetes (yes/no) 2.9 (2.2; 3.8)
P < 0.001
2.5 (1.9; 3.3)
P < 0.001
 Infertility (yes/no) 1.3 (1.1; 1.5)
P = 0.001
1.2 (1.0; 1.4)
P = 0.019
 Comorbidity 1.8 (1.5; 2.1)
P < 0.001
 OCP (yes/no) 1.0 (0.9; 1.1)
P = 0.661
1.0 (0.9; 1.1)
P = 0.687
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medium age at CVD diagnosis. Mani et al. [32] found a 
prevalence of 27% for myocardial infarction and angina 
in women with PCOS aged > 65 years attending a special-
ized clinic in United Kingdom and the OR for myocardial 
infarction was 12.9 in women with PCOS aged > 65 years 
vs. controls [32]. The risk for stroke was not significantly 
increased in PCOS in the meta-analysis by Anderson 
et  al., though the risk for stroke became significantly 
increased in PCOS when only studies in women of aver-
age age > 45  years were included [6]. Increasing age in 
PCOS was associated with higher blood pressure, more 
adverse lipid profile, and impaired beta cell function [29]. 
Therefore, the diagnosis pattern could differ significantly 
in peri- and postmenopausal study populations of women 
with PCOS. We could test this hypothesis by repeating 
the present study after longer follow up duration.
Androgen status
Testosterone levels at baseline did not predict develop-
ment of CVD. Accordingly, we recently reported that the 
presence of individual Rotterdam criteria was not associ-
ated with cardio-metabolic diagnoses upon diagnosis in 
Table 5 Crude and adjusted hazard ratios in PCOS OUH and development of CVD
Baseline characteristics in PCOS OUH and risk of development of CVD
Hazard ratios are presented for crude models and models corrected for age and BMI
BP blood pressure, LDL low density lipoprotein, HDL high density lipoprotein, 2 h: 2 hours (during oral glucose tolerance test), HOMA-ir homeostasis model assessment 
of insulin resistance, SHBG: Sex hormone-binding globulin
a Except age which is adjusted for BMI alone, and BMI which is adjusted for age alone
CVD CVD (HT and DL excluded)
Crude HR (95% CI) n Age and BMI
Adjusted  HRa (95% CI)
Crude HR (95% CI) n Age and BMI
Adjusted  HRa (95% CI)
Age (years) 1.1 (1.1; 1.1)
P < 0.001
1076 1.1 (1.1; 1.1)
P < 0.001
1.1 (1.1; 1.1)
P < 0.001
1076 1.1 (1.1; 1.1)
P < 0.001
BMI (kg/m2) 1.1 (1.0; 1.1)
P < 0.001
1076 1.1 (1.1; 1.1)
P < 0.001
1.1 (1.0; 1.1)
P < 0.001
1076 1.1 (1.1; 1.1)
P < 0.001
Waist (cm) 1.0 (1.0;1.0)
P < 0.001
710 1.0 (1.0; 1.0)
P = 0.02
1.0 (1.0;1.0)
P = 0.004
710 1.0 (1.0; 1.1)
P = 0.61
Systolic BP (mmHg) 1.0 (1.0; 1.1)
p < 0.001
730 1.0 (1.0; 1.0)
p < 0.001
1.0 (1.0; 1.1)
P = 0.001
730 1.0 (1.0; 1.0)
P = 0.09
Diastolic BP (mmHg) 1.1 (1.0; 1.1)
P < 0.001
729 1.0 (1.0; 1.1)
P < 0.001
1.1 (1.0; 1.1)
P < 0.001
729 1.0 (1.0; 1.1)
P = 0.06
LDL (mmol/l) 1.8 (1.6; 2.1)
P < 0.001
804 1.5 (1.2; 1.7)
P < 0.001
1.3 (1.0; 1.8)
P = 0.06
804 1.1 (0.7; 1.5)
P = 0.78
Cholesterol (mmol/L) 1.8 (1.6; 2.1)
P < 0.001
815 1.5 (1.3; 1.7)
P < 0.001
1.4 (1.0; 1.8)
P < 0.02
815 1.1 (0.8; 1.5)
P = 0.41
Triglycerides (mmol/L) 1.7 (1.4; 2.0)
P < 0.001
805 1.5 (1.2; 1.7)
P < 0.001
1.3 (0.9; 1.8)
P = 15
805 1.1 (0.7; 1.6)
P = 0.63
Prolactin (µg/L) 0.96 (0.9; 1.0)
P = 0.02
891 0.99 (0.95; 1.02)
P = 0.61
1.0 (0.9; 1.1)
P = 0.89
891 1.0 (1.0; 1.1)
P = 0.33
HbA1c (mmol/mol) 1.0 (1.0; 1.0)
P = 0.30
525 1.0 (1.0; 1.0)
P = 0.73
1.0 (1.0; 1.0)
P = 0.64
525 1.0 (1.0; 1.0)
P = 0.81
Fasting blood glucose (mmol/L) 1.5 (1.3; 1.8)
P < 0.001
510 1.3 (1.1; 1.5)
P = 0.001
1.5 (1.2; 2.0)
P = 0.001
510 1.2 (1.0; 1.7)
P = 0.15
2 h blood glucose (mmol/L) 1.2 (1.1; 1.3)
P < 0.001
497 1.1 (1.1; 1.2)
P < 0.001
1.2 (1.1; 1.3)
P = 0.003
497 1.1 (1.0; 1.2)
P = 0.12
Fasting insulin (pmol/L) 1.0 (1.0; 1.0)
P < 0.001
533 1.0 (1.0; 1.0)
P = 0.007
1.0 (1.0; 1.0)
P = 0.32
533 1.0 (1.0; 1.0)
P = 0.82
HOMA-ir (µg/L) 1.0 (1.0; 1.0)
P < 0.001
509 1.0 (1.0; 1.0)
P = 0.001
1.0 (1.0; 1.0)
P = 0.13
509 1.0 (1.0; 1.0)
P = 0.81
Total testosterone (nmol/L) 0.9 (0.8; 1.1)
P = 0.25
772 1.0 (0.9; 1.2)
P = 0.99
0.9 (0.7; 1.3)
P = 0.72
772 1.0 (0.8; 1.4)
P = 0.89
SHBG (nmol/L) 1.0 (1.0; 1.0)
P = 0.43
1000 1.0 (1.0; 1.0)
P = 0.30
1.0 (1.0; 1.0)
P = 0.77
1000 1.0 (1.0; 1.0)
P = 0.23
Free testosterone (nmol/L) 0.75 (0.01; 39.37)
P = 0.89
759 1.9 (0.03; 112.8)
P = 0.75
0.0 (0.0; 338.2)
P = 0.26
759 0.0 (0.0; 1858.0)
P = 0.36
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PCOS OUH despite a more adverse metabolic risk pro-
file in women with polycystic ovaries and irregular men-
ses [18]. Furthermore, testosterone levels did not predict 
the risk of T2D in PCOS OUH [10]. Importantly, mean 
BMI varies between different PCOS phenotypes [33, 34], 
and studies regarding vascular risk should adjust for BMI. 
Different results could be found in more obese study 
populations predominantly consisting of other PCOS 
phenotypes. Further prospective studies are needed to 
determine if the long-term cardiovascular risk is affected 
by PCOS phenotype independent of BMI.
OCP
OCP is often used to treat hyperandrogenism and irregu-
lar menses in PCOS. We found that treatment with OCP 
increased the risk of CVD in PCOS Denmark, but this 
became non-significant when dyslipidemia and hyper-
tension was not considered a CVD outcome. The most 
straightforward explanation would be that OCP is gen-
erally not prescribed for women with hypertension, but 
the register based design of the present study limits the 
possibility of firm conclusions regarding this point. The 
present study design did not allow us to adjust for use 
of OCP after the diagnosis of PCOS. However, our data 
confirmed increased risk of VTE in PCOS [16] and that 
the risk of CVD increased further during use of OCP [7, 
17]. Metabolic side-effects of OCP are a matter of dis-
cussion. We and others reported increased insulin levels 
during OGTT in women with PCOS treated with OCP 
[35, 36] along with weight gain [14], which could increase 
the risk of development of CVD. Furthermore, treat-
ment with OCP was associated with increased activa-
tion of the coagulation system [15], which was associated 
with increased thromboembolic risk [17]. The present 
data support that the possible benefit of OCP on PCOS-
related symptoms needs to be balanced against possible 
metabolic side effects in each patient.
Strengths and limitations
An important strength of this study was the nationwide 
data and the embedded cohort of PCOS OUH with 
available clinical and biochemical data, which allowed 
us to test hypotheses that could not be evaluated in the 
national cohort. Limitations to the study include the fol-
lowing. Women were diagnosed with PCOS through 
hospital contacts, hence some women in the control 
group may have undiagnosed PCOS, which could lead to 
underestimation of relative CVD risk in PCOS. However, 
undiagnosed PCOS likely represents milder cases. The 
Rotterdam criteria were introduced in 2003 [37], which 
implied the inclusion of more mild phenotypes as part of 
the PCOS definition. The use of different definitions of 
PCOS is a limitation of the present study. Furthermore, 
the study was conducted in a relatively lean and predomi-
nantly young Nordic study population with low baseline 
risk of CVD. Some ascertainment bias is possible, espe-
cially for potentially asymptomatic circulatory condi-
tions such as hypertension and dyslipidemia, with PCOS 
patients potentially having more BP and lipid measure-
ments done than population controls. The present study 
results need to be reproduced in study populations con-
sisting of other phenotypes and with higher baseline 
metabolic risk. Our definition of CVD as an outcome 
was relatively broad and included both prevalent condi-
tions such as hypertension and incident events such as 
myocardial infarction. We addressed this by defining a 
secondary study outcome without hypertension and dys-
lipidemia, and through tabulating the individual disease 
outcomes.
The present study design included baseline clinical and 
biochemical characteristics as predictors of CVD risk. 
PCOS is associated with higher serum levels of IL-6 and 
other inflammatory cytokines [2, 38], which could be 
associated with increased risk of CVD. Metabolic risk in 
PCOS could be related to IL-6 gene polymorphism [39] 
and the metabolic risk may be modified by lifestyle inter-
vention [40] and metformin treatment [41]. More studies 
are needed regarding the long term effect of lifestyle and 
medical intervention on CVD risk in PCOS. Potential 
improvements to cohort studies like this could include 
collection of more sophisticated measures of baseline 
inflammatory markers and prospective measures of for 
example BMI and glycemic status.
Conclusion
The risk of development of CVD was significantly 
increased in PCOS with hypertension as the most com-
mon cardiovascular diagnosis. The cardiovascular risk 
was predicted by baseline age and screening for the ele-
ments of the metabolic syndrome (BMI, BP, lipid sta-
tus, and glucose), and our data support that the risk of 
developing CVD must be considered even in young, 
lean women with PCOS. The risk of CVD was adversely 
affected by the use of OCP.
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